Pproves Zostavax vaccine shingles in people 50 to 59 years age PreventThe Food and Drug Administration today approved the use of Zostavax, a live virus vaccine to prevent shingles in individuals 50 to 59 years of age ciprofloxacin reviews . Zostavax is already in individuals 60 in individuals 60 years and older.
The approval was on a multi-center study in the United States and four other countries, some 22,000 50-59 years 50-59 years old were conducted. Half received Zostavax and half received a placebo. The study participants were then a year to a year to see if they developed shingles. Compared to placebo reduced the risk of developing Zostavax shingles by about 70 %.
The University of Texas MD Anderson Cancer Center , this message at the annual convention of the American Society for Clinical Oncology Convention presented.
Of Part A of trust fund bankruptcy closer mainly due to higher spending and lower tax revenues in the year 2003, and increased payments made to managed care and rural health facilities in the Medicare Modernization Act has moved. The prescription drug advantage that will start in 2006 below by a separate account in the Part W trust fund and is no effect on the part of an insolvency proceeding date.